Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN) Share News

AstraZeneca cancer drug Sone-Ve granted priority review by US FDA

19th Nov 2026 11:21

(Alliance News) - AstraZeneca PLC on Thursday said its biologics license application for cancer treatment sonesitatug vedotin, or Sone-Ve, has been accepted and granted priority review by the US Food & Drug Administration. Read More

AstraZeneca gets US, EU approvals for treatment of autoimmune disorder

16th Nov 2026 09:57

(Alliance News) - AstraZeneca PLC on Monday announced that Alexion's Klygefa treatment received approval in both the US and EU for adults with generalised myasthenia gravis, a rare autoimmune disorder that causes severe muscle weakness. Read More

LONDON BRIEFING: L&G upbeat on earnings; AstraZeneca wins approvals

16th Nov 2026 07:57

(Alliance News) - Legal & General expects full-year earnings growth to exceed its target range following positive third-quarter trading, while Coca-Cola HBC secures approval for a secondary listing in Johannesburg ahead of its Coca-Cola Beverages Africa acquisition. AstraZeneca receives US approval for its Imfinzi bladder cancer treatment and US and EU approvals for Klygefa. Read More

AstraZeneca says Baxfendy recommended for EU approval

13th Nov 2026 12:18

(Alliance News) - AstraZeneca PLC on Friday said the EU's Committee for Medicinal Products for Human Use has recommended Baxfendy, or baxdrostat, for approval as an arterial hypertension treatment. Read More

LONDON BROKER RATINGS: Berenberg raises Autotrader and likes Rightmove

9th Nov 2026 09:00

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday: Read More

LONDON MARKET OPEN: FTSE 100 slumps as global stocks sell off

6th Nov 2026 09:10

(Alliance News) - Stock prices in London opened sharply lower on Friday, with the FTSE 100 falling 1.5% as European markets followed a steep sell-off on Wall Street, while UK house prices recorded their largest annual decline in three years. Read More

LONDON BROKER RATINGS: Jefferies cuts Haleon; LBBW raises Shell target

4th Nov 2026 09:13

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More

CORRECT: Jefferies raises Centrica; Davy cuts Vistry

3rd Nov 2026 10:21

(Corrects currency for Magnum to EUR.) Read More

LONDON BROKER RATINGS: Jefferies raises Centrica; Davy cuts Vistry

3rd Nov 2026 09:21

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday: Read More

Hutchmed China hails Orpathys acceptance for review in Japan and EU

2nd Nov 2026 14:26

(Alliance News) - Hutchmed China Ltd on Monday said regulatory filings for Orpathys, alias savolitinib, in combination with Tagrisso have been accepted for review in Japan and the EU. Read More

LONDON BROKER RATINGS: Berenberg cuts Haleon, Barclays cuts Dr Martens

2nd Nov 2026 09:43

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday: Read More

LONDON MARKET CLOSE: FTSE 100 edges up but tech woe rocks New York

30th Oct 2026 17:01

(Alliance News) - London's FTSE 100 drifted in and out of positive territory in afternoon dealings before finally closing slightly higher on Friday, but equities across the Atlantic tumbled as worries over artificial intelligence sector spending sent tech stocks deeply into the red. Read More

LONDON MARKET MIDDAY: FTSE 100 edges up as EU growth beats forecasts

30th Oct 2026 11:59

(Alliance News) - Stock prices in London were mixed at midday on Friday, with the FTSE 100 edging higher as gains for telecommunications and pharmaceutical stocks offset a sharp fall for NatWest, while European markets diverged despite stronger-than-expected eurozone economic growth. Read More

WINNERS & LOSERS: BT jumps on network deal, NatWest drops on results

30th Oct 2026 11:12

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Friday. Read More

AstraZeneca shares rise as quarterly sales and profit top forecast

30th Oct 2026 10:28

(Alliance News) - AstraZeneca PLC on Friday delivered strong third quarter results with sales ahead of forecast and lower than expected costs driving an even more impressive profit beat. Read More

LONDON MARKET OPEN: FTSE 100 rises as AstraZeneca offsets bank losses

30th Oct 2026 09:08

(Alliance News) - Stock prices in London opened mixed on Friday, with the FTSE 100 rising as gains for AstraZeneca and BT Group offset losses for NatWest and Airtel Africa, while investors digested a contraction in the French economy. Read More

LONDON BRIEFING: AstraZeneca, BP and NatWest profits rise

30th Oct 2026 07:56

(Alliance News) - AstraZeneca, BP and NatWest report higher third-quarter pretax profits on Friday, while UK house price growth slows to its weakest pace since January 2024, according to figures from Nationwide. Read More

IN BRIEF: AstraZeneca's Enhertu receives EU approval

27th Oct 2026 08:55

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Says Enhertu, developed with Daiichi Sankyo Co Ltd, has been approved in the EU to treat adults with HER2-positive early breast cancer who have residual invasive disease following treatment before surgery. AstraZeneca says the European Commission approval follows results from the DESTINY-Breast05 phase III trial, presented in 2025, which showed Enhertu reduced the risk of invasive disease recurrence or death by 53% compared with T-DM1. Following approval, AstraZeneca will pay Daiichi Sankyo USD75 million as a milestone payment. Read More

AstraZeneca highlights advances across cancer portfolio at ESMO 2026

26th Oct 2026 09:39

(Alliance News) - AstraZeneca PLC on Saturday and Sunday reported a series of positive clinical trial results for ongoing clinical trials at the European Society for Medical Oncology Congress 2026 in Madrid. Read More

LONDON BRIEFING: Computacenter lifts outlook, Plus500 upbeat

26th Oct 2026 07:58

(Alliance News) - Computacenter raises its full-year profit outlook after strong third-quarter trading, while Plus500 forecast annual revenue and earnings ahead of market expectations. GSK has reported positive clinical trial results for two cancer treatments. Read More

FTSE 100 Latest
Value10,509.88
Change-41.29